← Eichor
Condition: Unresectable Biliary Tract Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Biliary Tract Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic C
NA · 8 location(s) · Aichi Medical University · NCT07235007A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G
Phase N/A · 1 location(s) · Eisai Co., Ltd. · NCT06793709QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Phase 2 · 1 location(s) · Eastern Hepatobiliary Surgery Hospital · NCT06892925Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Phase 2 · 1 location(s) · Columbia University · NCT07433673Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT06893380Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined wi
Phase N/A · 2 location(s) · Zhongda Hospital · NCT06849193Radiation Therapy in Unresectable Gall Bladder Cancer
Phase 2/Phase 3 · 1 location(s) · Tata Memorial Centre · NCT06214572Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unr
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06852287Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Local
Phase 2 · 1 location(s) · Xiujuan Qu · NCT07506057Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Phase 2 · 1 location(s) · National Cancer Center, Korea · NCT06135896Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as S
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07530445PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Color
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05286814Observational Study Protocol: LIVER-R
Phase N/A · 159 location(s) · AstraZeneca · NCT06252753Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Trac
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07636798Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Phase 4 · 20 location(s) · University of Leipzig · NCT05551299Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Chola
Phase 2 · 1 location(s) · Jinbo Yue · NCT07030140Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Phase 2 · 4 location(s) · Insel Gruppe AG, University Hospital Bern · NCT06274879Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07641036A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Phase 2 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07450976Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Phase 3 · 6 location(s) · Tata Memorial Centre · NCT07062263Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Phase 2 · 1 location(s) · Lu Wang, MD, PhD · NCT05757336Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cance
Phase 2 · 1 location(s) · Air Force Military Medical University, China · NCT07569679A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
NA · 1 location(s) · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · NCT06611345A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Phase 2 · 1 location(s) · Beth Israel Deaconess Medical Center · NCT05655949Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 · 12 location(s) · Replimune, Inc. · NCT05733598Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma
NA · 1 location(s) · Oslo University Hospital · NCT04993131A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili
Phase 3 · 174 location(s) · AstraZeneca · NCT07221253CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Bi
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06548412A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial
Phase 2 · 1 location(s) · Yongjun Chen · NCT07135544
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.